Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Advances in Therapy|November 25, 2021
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell LymphomaDivya Samineni, Weize Huang, Leonid Gibiansky, et al.
Journal of Medicinal Chemistry|February 27, 2016
Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid HydroxylasePhilippe Diaz, Weize Huang, Charles M Keyari, et al.
Pharmaceutical Research|September 13, 2023
Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney DiseaseShih-Yu Chang, Weize Huang, Alenka Chapron, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 7, 2023
CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive MetabolizersLindsay C Czuba, Karan Malhotra, Luke Enthoven, et al.
Frontiers in Pharmacology|October 13, 2022
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumorsWeize Huang, Felix Stader, Phyllis Chan, et al.
Journal of Clinical Pharmacology|October 30, 2022
Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 ActivityOgochukwu U Amaeze, Lindsay C Czuba, Aprajita S Yadav, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Pageof 3